Long-Term Safety and Efficacy

Clayton et al. (2022) conducted an open-label extension following 684 women for up to 18 months. Efficacy was sustained without tachyphylaxis at median usage of 2-3 doses per month. Nausea incidence declined from approximately 40% initially to approximately 18% by month 12, likely reflecting MC4R desensitization in brainstem emetic centers. No cardiovascular safety signals emerged with long-term use.

Male Erectile Dysfunction

Diamond et al. (2004) demonstrated efficacy of intranasal bremelanotide in a placebo-controlled trial in 20 men with mild-to-moderate ED. RigiScan monitoring showed clinically significant erectile responses (rigidity >60% at tip and base for >5 minutes) in 67% of subjects, including men with diabetes-related ED and post-prostatectomy patients who had failed sildenafil. The central mechanism enables efficacy independent of peripheral vascular function.

Hemorrhagic Shock

Giuliani et al. (2012) demonstrated organ-protective effects of melanocortin agonists including bremelanotide in rodent hemorrhagic shock models. MC4R activation reduced inflammatory cytokine production (TNF-alpha, IL-6), neutrophil infiltration, and organ injury through NF-kappaB inhibition, suggesting potential critical care applications.

Intranasal Efficacy in Female Sexual Arousal

Diamond et al. (2006) administered intranasal PT-141 at 10 mg and 20 mg doses to premenopausal women with female sexual arousal disorder (FSAD) in a randomized, double-blind, placebo-controlled crossover design (n=18). Vaginal photoplethysmography measured genital blood flow during exposure to erotic visual stimuli. The 20 mg intranasal dose produced significant increases in vaginal pulse amplitude (p<0.05) and subjective arousal scores compared to placebo. These data confirmed that the central melanocortin mechanism produces measurable physiological arousal responses in women via the nasal route.

Intranasal Efficacy in Male Erectile Dysfunction

Diamond et al. (2004) conducted the pivotal intranasal PT-141 study: a double-blind, placebo-controlled evaluation in 20 men with mild-to-moderate erectile dysfunction. Intranasal doses of 7 mg and 20 mg were tested. RigiScan monitoring showed that 67% of subjects achieved clinically significant erectile responses (rigidity >60% at both base and tip for >5 minutes) at the 20 mg dose, compared to 20% with placebo. Remarkably, the study included men with diabetes-related ED and post-prostatectomy patients who had previously failed sildenafil — populations where PDE5 inhibitors typically show poor response rates.

The onset of erectile response occurred within 15-30 minutes of intranasal administration, significantly faster than the 45-60 minutes typically required for subcutaneous delivery. Duration of effect was approximately 4-6 hours from the nasal dose.

Blood Pressure Concerns and Route Switch

Clinical data across multiple intranasal trials consistently showed transient systolic blood pressure increases of 6-12 mmHg and diastolic increases of 4-8 mmHg within 30-60 minutes of intranasal dosing. While these elevations were self-limiting (resolving within 2-4 hours), the FDA's Division of Bone, Reproductive and Urologic Products expressed concern about cardiovascular risk in patients with undiagnosed or poorly controlled hypertension using an on-demand sexual dysfunction treatment.

Palatin Technologies subsequently demonstrated that subcutaneous delivery of 1.75 mg bremelanotide produced smaller blood pressure effects (mean systolic increase ~3 mmHg, diastolic ~2 mmHg) with a more gradual pharmacokinetic profile. The SC formulation was advanced through Phase 3 RECONNECT trials and received FDA approval in June 2019 as Vyleesi.

Bioavailability Comparison: Intranasal vs Subcutaneous

Pharmacokinetic studies comparing the two routes revealed critical differences:

• Intranasal (7-20 mg): Tmax 15-30 min, bioavailability ~5-10%, variable absorption (CV 40-60%), Cmax/AUC ratio indicating rapid spike-and-decline profile
• Subcutaneous (1.75 mg): Tmax ~60 min, bioavailability ~100%, consistent absorption (CV 15-25%), smoother pharmacokinetic profile

The low intranasal bioavailability (~5-10%) required doses 4-10 fold higher than SC to achieve equivalent systemic exposure. However, the rapid Tmax created disproportionately high peak concentrations relative to total drug exposure, which drove the blood pressure signal.

Neural Pathway Integration

The neuropeptide systems do not operate in isolation. The integrated model of erectile neural control involves:

1. Central initiation: Psychogenic arousal activates the MPOA/PVN, which sends descending signals via the spinal cord to the sacral parasympathetic nucleus (S2–S4)
2. Parasympathetic activation: Cavernous nerve stimulation releases NO and VIP, producing active corporal relaxation
3. Sensory amplification: Tactile stimulation releases CGRP and substance P from sensory terminals, reinforcing local vasodilation through the reflex arc
4. Sympathetic withdrawal: Parasympathetic activation reciprocally inhibits sympathetic outflow, reducing norepinephrine and NPY release
5. Detumescence: Sympathetic reactivation releases norepinephrine and NPY, producing contraction and resumption of flaccidity

Giuliano & Rampin (2000) mapped these integrated circuits in rodent models, demonstrating that selective lesioning of specific neuropeptide pathways produces predictable erectile deficits.

Diabetic Neuropathy and Erectile Dysfunction

Diabetes mellitus produces selective neuropathic damage to penile nerve populations. Immunohistochemical studies reveal significant loss of VIP-containing and CGRP-containing nerve fibers in diabetic corporal tissue, while NPY-containing sympathetic fibers are relatively spared. This creates a pathological imbalance: reduced pro-erectile NANC/sensory neuropeptide tone with maintained anti-erectile sympathetic tone. Lincoln et al. (1987) demonstrated selective VIP nerve fiber depletion in penile tissue from diabetic men, providing a neuropeptide-based explanation for the high prevalence of ED in diabetes (50–75%).

Spinal Cord Injury Models

Spinal cord injury (SCI) disrupts descending supraspinal input while variably preserving local reflex arcs. In complete SCI above the sacral segments, psychogenic erection is lost but reflex erection (mediated by local sensory neuropeptide release — CGRP, substance P) may be preserved. Conversely, sacral SCI damages the local parasympathetic pathways (VIP, NO release) while preserving psychogenic pathways. This dissociation has been critical for understanding the relative contributions of different neuropeptide systems to erectile function (Biering-Sorensen & Sonksen, 2001).

Central vs Peripheral Mechanisms

Neuropeptides participate in erectile regulation at both central and peripheral levels. Centrally, VIP acts in the PVN to facilitate oxytocin release and pro-erectile descending signaling. NPY in the MPOA modulates sexual motivation and copulatory behavior. CGRP in the dorsal horn of the spinal cord processes penile sensory afferents. Peripherally, these same peptides act directly on corporal smooth muscle and vasculature as described above. The dual central-peripheral roles make neuropeptide systems complex but potentially powerful therapeutic targets (Giuliano et al., 1993).

Phase III RECONNECT Trials (HSDD)

Kingsberg et al. (2019) reported results from two pivotal randomized, double-blind, placebo-controlled Phase III trials (Studies 301 and 302) enrolling 1,247 premenopausal women with generalized acquired HSDD. Patients self-administered bremelanotide 1.75 mg SC as needed for 24 weeks. Primary endpoints were change in satisfying sexual events (SSE) per month and Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score. Bremelanotide significantly increased SSEs (mean increase 1.0 over placebo, p<0.001) and reduced sexual distress scores. Approximately 25% of bremelanotide-treated patients achieved clinically meaningful improvement versus 17% for placebo.

Female Sexual Arousal

Diamond et al. (2006) used vaginal photoplethysmography to measure genital arousal in premenopausal women with female sexual arousal disorder (FSAD). Intranasal bremelanotide at 20 mg significantly increased vaginal pulse amplitude during erotic visual stimulation compared to placebo (p<0.05), confirming physiological arousal effects in women.

Hypoactive Sexual Desire Disorder (HSDD)

The pivotal RECONNECT Phase 3 clinical trials (Studies 301 and 302) enrolled over 1,247 premenopausal women with HSDD. Kingsberg et al. (2019) reported that PT-141 (1.75 mg subcutaneous injection, administered as needed at least 45 minutes before anticipated sexual activity) significantly increased the number of satisfying sexual events (SSEs) and improved scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared to placebo. Approximately 25% of PT-141-treated patients experienced clinically meaningful improvement in desire, compared to 17% in the placebo group (p&lt;0.001). These trials formed the basis for FDA approval in June 2019.

The FDA label limits use to no more than one dose per 24 hours and no more than 8 doses per month due to concerns about tachyphylaxis and blood pressure effects with frequent dosing.

Hemorrhagic Shock and Organ Protection

Research in animal models has revealed that melanocortin agonists including PT-141 may have significant applications beyond sexual function. Giuliani et al. (2007) demonstrated that MC4R activation in rodent hemorrhagic shock models reduced organ injury and improved survival rates. The protective effects appear mediated through:

• Inhibition of NF-kappaB-dependent inflammatory signaling
• Reduced neutrophil infiltration into organs
• Decreased production of TNF-alpha, IL-6, and other pro-inflammatory cytokines
• Improved cardiovascular function during hemorrhagic resuscitation

These findings have spurred interest in melanocortin agonists as potential emergency medicine therapeutics for trauma and shock.

Melanocortin Signaling and Energy Homeostasis

PT-141 has been used extensively as a pharmacological tool to study melanocortin receptor function. Cone (2006) reviewed the expanding roles of MC3R and MC4R in energy homeostasis, feeding behavior, cardiovascular regulation, and inflammation. Research using PT-141 and related melanocortin agonists has elucidated:

• MC4R's role as a critical mediator of leptin's anorexigenic effects
• Melanocortin involvement in cardiovascular autonomic regulation
• MC3R's distinct role in energy partitioning and fat storage
• Central melanocortin influence on inflammatory responses

Female Sexual Arousal Disorder

Beyond HSDD, PT-141 has been investigated for female sexual arousal disorder (FSAD). Diamond et al. (2006) conducted a study using vaginal photoplethysmography to measure genital arousal in women exposed to erotic stimuli after PT-141 administration. Results showed significant increases in vaginal blood flow and subjective arousal compared to placebo, confirming that PT-141's central mechanism produces measurable physiological arousal responses in women.